Published in Drug Discov Today on December 01, 2005
DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res (2007) 13.94
DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res (2010) 13.68
An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov (2012) 5.55
PubChem as a public resource for drug discovery. Drug Discov Today (2010) 3.40
PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics (2008) 2.35
DGIdb: mining the druggable genome. Nat Methods (2013) 2.26
Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins. Nat Chem Biol (2011) 1.98
Chemogenomic approaches to rational drug design. Br J Pharmacol (2007) 1.74
Microfluidics for drug discovery and development: from target selection to product lifecycle management. Drug Discov Today (2007) 1.71
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation (2007) 1.70
Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol (2012) 1.55
A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy. Mol Cell (2016) 1.45
In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni. PLoS Negl Trop Dis (2015) 1.42
Blueprint for antimicrobial hit discovery targeting metabolic networks. Proc Natl Acad Sci U S A (2010) 1.42
DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res (2015) 1.41
Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res (2016) 1.38
How chemoproteomics can enable drug discovery and development. Chem Biol (2012) 1.27
Computational prediction of essential genes in an unculturable endosymbiotic bacterium, Wolbachia of Brugia malayi. BMC Microbiol (2009) 1.22
SuperPred: drug classification and target prediction. Nucleic Acids Res (2008) 1.14
Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases. Chem Biol (2012) 1.13
Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol (2009) 1.11
A mapping of drug space from the viewpoint of small molecule metabolism. PLoS Comput Biol (2009) 1.09
Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds. J Cheminform (2009) 1.08
Meta-analysis approach identifies candidate genes and associated molecular networks for type-2 diabetes mellitus. BMC Genomics (2008) 1.08
Classification of scaffold-hopping approaches. Drug Discov Today (2011) 1.04
Self-assembly of a simple membrane protein: coarse-grained molecular dynamics simulations of the influenza M2 channel. Biophys J (2008) 1.03
Design of DNA minor groove binding diamidines that recognize GC base pair sequences: a dimeric-hinge interaction motif. J Am Chem Soc (2007) 1.02
Prediction of potential drug targets based on simple sequence properties. BMC Bioinformatics (2007) 1.01
Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci U S A (2013) 1.01
New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics. Evid Based Complement Alternat Med (2013) 1.00
High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes. Bone Res (2014) 0.98
Distribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discovery. Genome Biol (2007) 0.98
Differences between high- and low-affinity complexes of enzymes and nonenzymes. J Med Chem (2008) 0.97
Large-scale functional RNAi screen in C. elegans identifies genes that regulate the dysfunction of mutant polyglutamine neurons. BMC Genomics (2012) 0.96
Exome sequencing identifies frequent mutation of MLL2 in non-small cell lung carcinoma from Chinese patients. Sci Rep (2014) 0.95
In vitro selection of highly modified cyclic peptides that act as tight binding inhibitors. J Am Chem Soc (2012) 0.94
Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. Mol Psychiatry (2015) 0.93
Differential membrane proteomics using 18O-labeling to identify biomarkers for cholangiocarcinoma. J Proteome Res (2008) 0.92
Rapid analysis of pharmacology for infectious diseases. Curr Top Med Chem (2011) 0.92
Novel HIV-1 knockdown targets identified by an enriched kinases/phosphatases shRNA library using a long-term iterative screen in Jurkat T-cells. PLoS One (2010) 0.91
Identifying druggable disease-modifying gene products. Curr Opin Chem Biol (2009) 0.91
Systems pharmacology. Mt Sinai J Med (2010) 0.90
Ligand discovery and virtual screening using the program LIDAEUS. Br J Pharmacol (2007) 0.89
siRNA Genome Screening Approaches to Therapeutic Drug Repositioning. Pharmaceuticals (Basel) (2013) 0.89
Chromatographic benefits of elevated temperature for the proteomic analysis of membrane proteins. Proteomics (2008) 0.89
Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders. Annu Rev Pharmacol Toxicol (2015) 0.89
Fluorine-19 NMR of integral membrane proteins illustrated with studies of GPCRs. Curr Opin Struct Biol (2013) 0.89
Integrating statistical predictions and experimental verifications for enhancing protein-chemical interaction predictions in virtual screening. PLoS Comput Biol (2009) 0.88
Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development. PLoS One (2011) 0.88
Drug target predictions based on heterogeneous graph inference. Pac Symp Biocomput (2013) 0.88
Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data. PLoS One (2013) 0.86
AlignMe--a membrane protein sequence alignment web server. Nucleic Acids Res (2014) 0.86
Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. Antimicrob Agents Chemother (2012) 0.86
Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors. Bioengineered (2012) 0.85
The Wnt receptor Ryk reduces neuronal and cell survival capacity by repressing FOXO activity during the early phases of mutant huntingtin pathogenicity. PLoS Biol (2014) 0.85
Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations. Hum Mol Genet (2013) 0.84
Properties of protein drug target classes. PLoS One (2015) 0.84
ModEnzA: Accurate Identification of Metabolic Enzymes Using Function Specific Profile HMMs with Optimised Discrimination Threshold and Modified Emission Probabilities. Adv Bioinformatics (2011) 0.83
Mining significant substructure pairs for interpreting polypharmacology in drug-target network. PLoS One (2011) 0.83
Hyaluronan (HA) interacting proteins RHAMM and hyaluronidase impact prostate cancer cell behavior and invadopodia formation in 3D HA-based hydrogels. PLoS One (2012) 0.83
Biophysical characterization of G-protein coupled receptor-peptide ligand binding. Biochem Cell Biol (2011) 0.83
Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth. J Cancer Res Clin Oncol (2012) 0.82
Genomics and bioinformatics of Parkinson's disease. Cold Spring Harb Perspect Med (2012) 0.82
Chemical biology: Greasy tags for protein removal. Nature (2012) 0.81
Integration and mining of malaria molecular, functional and pharmacological data: how far are we from a chemogenomic knowledge space? Malar J (2006) 0.81
Large-scale reverse docking profiles and their applications. BMC Bioinformatics (2012) 0.81
iFad: an integrative factor analysis model for drug-pathway association inference. Bioinformatics (2012) 0.81
Benchmarking human protein complexes to investigate drug-related systems and evaluate predicted protein complexes. PLoS One (2013) 0.81
MOfinder: a novel algorithm for detecting overlapping modules from protein-protein interaction network. J Biomed Biotechnol (2012) 0.80
Molecular simulation methods in drug discovery: a prospective outlook. J Comput Aided Mol Des (2011) 0.80
TARGETgene: a tool for identification of potential therapeutic targets in cancer. PLoS One (2012) 0.80
The molecular genomics of metastatic brain tumours. OA Mol Oncol (2013) 0.80
Scaling the druggability landscape of human bromodomains, a new class of drug targets. J Med Chem (2012) 0.80
Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? Dialogues Clin Neurosci (2006) 0.79
Meta-basic estimates the size of druggable human genome. J Mol Model (2008) 0.79
Hydrophobic Fractionation Enhances Novel Protein Detection by Mass Spectrometry in Triple Negative Breast Cancer. J Proteomics Bioinform (2010) 0.79
Druggability: selecting optimized drug candidates. Drug Discov Today (2005) 0.78
Drug Normalization for Cancer Therapeutic and Druggable Genome Target Discovery. AMIA Jt Summits Transl Sci Proc (2015) 0.78
Progress towards mechanism-based treatment for Diamond-Blackfan anemia. ScientificWorldJournal (2012) 0.78
Pathways to decoding the clinical potential of stress response FOXO-interaction networks for Huntington's disease: of gene prioritization and context dependence. Front Aging Neurosci (2013) 0.78
New Frontiers in Druggability. J Med Chem (2015) 0.77
Quantum Mechanics Approaches to Drug Research in the Era of Structural Chemogenomics. Int J Quantum Chem (2013) 0.77
Expression profiling of drug response--from genes to pathways. Dialogues Clin Neurosci (2006) 0.77
Neurobiological applications of small molecule screening. Chem Rev (2008) 0.77
TNF superfamily protein-protein interactions: feasibility of small- molecule modulation. Curr Drug Targets (2015) 0.77
Targeted Protein Degradation by Small Molecules. Annu Rev Pharmacol Toxicol (2016) 0.77
Evolutionary survey of druggable protein targets with respect to their subcellular localizations. Genome Biol Evol (2013) 0.76
Biophysical screening for the discovery of small-molecule ligands. Methods Mol Biol (2013) 0.76
CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of Cryptic Binding Sites. J Mol Biol (2016) 0.76
Community structure detection for overlapping modules through mathematical programming in protein interaction networks. PLoS One (2014) 0.75
Functional and Genomic Features of Human Genes Mutated in Neuropsychiatric Disorders. Open Neurol J (2016) 0.75
Multi-algorithm and multi-model based drug target prediction and web server. Acta Pharmacol Sin (2014) 0.75
Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science (2003) 4.40
A biological transporter for the delivery of peptide nucleic acids (PNAs) to the nuclear compartment of living cells. J Mol Biol (2002) 1.18
Automated screening for genomic imbalances using matrix-based comparative genomic hybridization. Lab Invest (2002) 1.10